Table 3. Significant associations between toxicities and clinical variables or SNPs.
| Toxicity | Variable | Groups | All patients | ddAC | TAC | TAC vs ddAC | Test for interaction | |||
|---|---|---|---|---|---|---|---|---|---|---|
| No. of patients with toxicity (%) | OR (95% CI) | p-value | No. of patients with toxicity (%) | No. of patients with toxicity (%) | OR (95% CI) | p-value | p-value | |||
| AN | Age9 | < 65 years vs ≥ 65 years |
68/616 (11.0) 9/30 (30.0) |
3.45 (1.52-7.85) | 0.003 | 56/310 (18.1) 6/17 (35.3) |
12/306 (3.9) 3/13 (23.1) |
0.19 (0.10-0.35) 0.55 (0.11-2.81) |
< 0.001 0.472 |
0.223 |
| AN | Baseline platelet count9 | > 200x109 cells/L vs ≤ 200x109 cells/L |
63/585 (10.8) 14/55 (25.5) |
2.83 (1.46-5.48) | 0.002 | 52/294 (17.7) 10/28 (35.7) |
11/291 (3.8) 4/27 (14.8) |
0.18 (0.09-0.36) 0.31 (0.08-1.16) |
< 0.001 0.083 |
0.475 |
| FN | FGFR4 (rs351855) | CC/CT vs TT |
66/579 (11.4) 8/59 (13.6) |
1.22 (0.55-2.68) | 0.622 | 28/293 (9.6) 7/30 (23.3) |
38/286 (13.3) 1/29 (3.4) |
1.45 (0.86-2.43) 0.12 (0.01-1.02) |
0.160 0.053 |
0.027 |
| PNP | TECTA(rs1829)28 | CC/CT vs TT |
52/608 (8.6) 9/32 (28.1) |
4.18 (1.84-9.51) | 0.001 | 14/315 (4.4) 1/9 (11.1) |
38/293 (13.0) 8/23 (34.8) |
3.20 (1.70-6.05) 4.27 (0.45-40.44) |
< 0.001 0.206 |
0.810 |
| PNP | GSTP1 (rs1138272)31 | CC vs CT/TT |
43/525 (8.2) 18/117 (15.4) |
2.04 (1.13-3.68) | 0.018 | 11/275 (4.0) 4/50 (8.0) |
32/250 (12.8) 14/67 (20.9) |
3.52 (1.74-7.15) 3.04 (0.93-9.88) |
< 0.001 0.065 |
0.833 |
ddAC = dose-dense doxorubicin, cyclophosphamide; TAC = docetaxel, doxorubicin, cyclophosphamide; OR = odds ratio; CI = confidence interval.